PPAR agonists as therapeutics for CNS trauma and neurological diseases.
paper
Cited
Public
- Authors
- Mandrekar-Colucci, Shweta; Sauerbeck, Andrew; Popovich, Phillip G; McTigue, Dana M
- Year
- 2013
- Journal
- ASN neuro
- PMID
- 24215544
- DOI
- 10.1042/AN20130030
- PMCID
- PMC3866683
Traumatic injury or disease of the spinal cord and brain elicits multiple cellular and biochemical reactions that together cause or are associated with neuropathology. Specifically, injury or disease elicits acute infiltration and activation of immune cells, death of neurons and glia, mitochondrial dysfunction, and the secretion of substrates that inhibit axon regeneration. In some diseases, inflammation is chronic or non-resolving. Ligands that target PPARs (peroxisome proliferator-activated receptors), a group of ligand-activated transcription factors, are promising therapeutics for neurologic disease and CNS injury because their activation affects many, if not all, of these interrelated pathologic mechanisms. PPAR activation can simultaneously weaken or reprogram the immune response, stimulate metabolic and mitochondrial function, promote axon growth and induce progenitor cells to differentiate into myelinating oligodendrocytes. PPAR activation has beneficial effects in many pre-clinical models of neurodegenerative diseases and CNS injury; however, the mechanisms through which PPARs exert these effects have yet to be fully elucidated. In this review we discuss current literature supporting the role of PPAR activation as a therapeutic target for treating traumatic injury and degenerative diseases of the CNS.
PPARs modulate multiple pathways in the CNSPPAR activation after CNS injury/trauma promotes recovery through multiple mechanisms by promoting (1) axon outgrowth, (2) mitochondrial bioenergetics, (3) inhibition of Th1 and Th17 T-cell differentiation, (4) OPC maturation, and (5) polarization of macrophages from an inflammatory ‘M1’ to an anti-inflammatory ‘M2’ activation state.
NG2+ oligodendrocyte progenitor cells express PPARδSpinal cord section from a normal rat spinal cord gray matter (ventral horn) immunolabeled for PPARδ (brown) and NG2 (gray), a marker for oligodendrocyte progenitor cells. In the normal spinal cord, PPARδ is expressed by NG2 cells (arrow, inset) and is also visible in NG2-negative motor neurons (arrowheads). Scale bar=50 μm; scale bar in inset=20 μm.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | 2015 | 25516156 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Nuclear receptors in age-related diseases: From mechanisms to drug discovery. | Zhang L et al. | — | 2026 | → |
| Kaempferol Regulates Lipid Homeostasis, Endocannabinoid System, and PPARα in Rat Cerebral Cortex Following BCCAO/R. | Carta G et al. | — | 2025 | → |
| Repair mechanisms of the central nervous system: From axon sprouting to remyelination. | Gluck L et al. | — | 2025 | → |
| Unlocking the Neuroprotective Effect of Quercetin Against Cadmium-Induced Hippocampal Damage in Rats: PPARγ Activation as a Key Mechanism. | Al-Nouri DM | — | 2025 | → |
| Unraveling the Function of PPARα in Neurodegenerative Disorders: A Potential Pathway to Novel Therapies. | Galanou ON et al. | — | 2025 | → |
| Formulation of Solid Lipid Nanoparticles Loaded with Rosiglitazone and Probiotic: Optimization and <i>In-vitro</i> Characterization. | Kumar N et al. | — | 2024 | → |
| PPARα suppresses low-intensity-noise-induced body weight gain in mice: the activated HPA axis plays an critical role. | Yan Z et al. | — | 2024 | → |
| Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate. | Pizcueta P et al. | — | 2023 | → |
| Myelin lipid metabolism and its role in myelination and myelin maintenance. | Barnes-Vélez JA et al. | — | 2023 | → |
| Redox Imbalance as a Common Pathogenic Factor Linking Hearing Loss and Cognitive Decline. | Paciello F et al. | — | 2023 | → |
| Co-Ultramicronized Palmitoylethanolamide/Luteolin Restores Oligodendrocyte Homeostasis via Peroxisome Proliferator-Activated Receptor-α in an In Vitro Model of Alzheimer's Disease. | Facchinetti R et al. | — | 2022 | → |
| Effects of a Novel Beta Lactam Compound, MC-100093, on the Expression of Glutamate Transporters/Receptors and Ethanol Drinking Behavior of Alcohol-Preferring Rats. | Alhaddad H et al. | — | 2022 | → |
| New Therapeutic Approaches to and Mechanisms of Ginsenoside Rg1 against Neurological Diseases. | Sun Y et al. | — | 2022 | → |
| Novel role of peroxisome proliferator activated receptor-α in valproic acid rat model of autism: Mechanistic study of risperidone and metformin monotherapy versus combination. | Elnahas EM et al. | — | 2022 | → |
| Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors. | Terziev R et al. | — | 2021 | → |
| Depichering the Effects of Astragaloside IV on AD-Like Phenotypes: A Systematic and Experimental Investigation. | Wang X et al. | — | 2021 | → |
| Dose-dependent effects of prenatal exposure of pioglitazone, the PPARγ agonist, on the hippocampus development and learning and memory performance of rat offspring. | Sağır D | — | 2021 | → |
| High-Fat Diet Alleviates Neuroinflammation and Metabolic Disorders of APP/PS1 Mice and the Intervention With Chinese Medicine. | Fan X et al. | — | 2021 | → |
| Impact of ibuprofen and peroxisome proliferator-activated receptor gamma on emotion-related neural activation: A randomized, placebo-controlled trial. | Cosgrove KT et al. | — | 2021 | → |
| Insulin Resistance and Blood-Brain Barrier Dysfunction Underlie Neuroprogression in Bipolar Disorder. | Calkin C et al. | — | 2021 | → |
| In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation. | Chang KH et al. | — | 2021 | → |
| Lipoprotein Lipase Regulates Microglial Lipid Droplet Accumulation. | Loving BA et al. | — | 2021 | → |
| Neuroprotective Effect of Cyclo-(L-Pro-L-Phe) Isolated from the Jellyfish-Derived Fungus <i>Aspergillus flavus</i>. | Li DD et al. | — | 2021 | → |
| Noise-Induced Cochlear Damage Involves PPAR Down-Regulation through the Interplay between Oxidative Stress and Inflammation. | Paciello F et al. | — | 2021 | → |
| Nuclear Receptors in Myocardial and Cerebral Ischemia-Mechanisms of Action and Therapeutic Strategies. | Rzemieniec J et al. | — | 2021 | → |
| Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-ɣ): Molecular Effects and Its Importance as a Novel Therapeutic Target for Cerebral Ischemic Injury. | Mannan A et al. | — | 2021 | → |
| Profiling sensory neuron microenvironment after peripheral and central axon injury reveals key pathways for neural repair. | Avraham O et al. | — | 2021 | → |
| Targeting white matter neuroprotection as a relapse prevention strategy for treatment of cocaine use disorder: Design of a mechanism-focused randomized clinical trial. | Schmitz JM et al. | — | 2021 | → |
| What are activated and reactive glia and what is their role in neurodegeneration? | Bennett ML et al. | — | 2021 | → |
| Amino acid metabolism, lipid metabolism, and oxidative stress are associated with post-stroke depression: a metabonomics study. | Wang M et al. | — | 2020 | → |
| Astragaloside IV prevents Aβ<sub>1-42</sub> oligomers-induced memory impairment and hippocampal cell apoptosis by promoting PPARγ/BDNF signaling pathway. | Wang X et al. | — | 2020 | → |
| Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites. | HD iPSC Consortium | — | 2020 | → |
| Management of Traumatic Brain Injury: From Present to Future. | Crupi R et al. | — | 2020 | → |
| Minutes of PPAR-γ agonism and neuroprotection. | Prashantha Kumar BR et al. | — | 2020 | → |
| Role of peroxisome proliferator-activated receptors in stroke prevention and therapy-The best is yet to come? | Gamdzyk M et al. | — | 2020 | → |
| The PPAR <i>Ω</i> Pocket: Renewed Opportunities for Drug Development. | Kaupang Å et al. | — | 2020 | → |
| Angiotensin II type 2 receptor stimulation with compound 21 improves neurological function after stroke in female rats: a pilot study. | Eldahshan W et al. | — | 2019 | → |
| Peroxisome Proliferator-Activated Receptor γ Agonist Rosiglitazone Protects Blood-Brain Barrier Integrity Following Diffuse Axonal Injury by Decreasing the Levels of Inflammatory Mediators Through a Caveolin-1-Dependent Pathway. | Zhao Y et al. | — | 2019 | → |
| PPAR-γ agonist GL516 reduces oxidative stress and apoptosis occurrence in a rat astrocyte cell line. | Giampietro L et al. | — | 2019 | → |
| Resveratrol Regulates BDNF, trkB, PSA-NCAM, and Arc Expression in the Rat Cerebral Cortex after Bilateral Common Carotid Artery Occlusion and Reperfusion. | Serra MP et al. | — | 2019 | → |
| The Medical Management of Cerebral Edema: Past, Present, and Future Therapies. | Halstead MR et al. | — | 2019 | → |
| A Precision Medicine Approach to Cerebral Edema and Intracranial Hypertension after Severe Traumatic Brain Injury: Quo Vadis? | Jha RM et al. | — | 2018 | → |
| Cell death after traumatic brain injury: Detrimental role of anoikis in healing. | Sater AP et al. | — | 2018 | → |
| Emerging Therapeutic Role of PPAR-α in Cognition and Emotions. | Nisbett KE et al. | — | 2018 | → |
| Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair. | Cai W et al. | — | 2018 | → |
| Polarization of Microglia to the M2 Phenotype in a Peroxisome Proliferator-Activated Receptor Gamma-Dependent Manner Attenuates Axonal Injury Induced by Traumatic Brain Injury in Mice. | Wen L et al. | — | 2018 | → |
| PPARβ/δ: Linking Metabolism to Regeneration. | Magadum A et al. | — | 2018 | → |
| Preventive Effects of Resveratrol on Endocannabinoid System and Synaptic Protein Modifications in Rat Cerebral Cortex Challenged by Bilateral Common Carotid Artery Occlusion and Reperfusion. | Carta G et al. | — | 2018 | → |
| Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation. | Villapol S | — | 2018 | → |
| Astrocyte-Specific Deletion of Peroxisome-Proliferator Activated Receptor-<i>γ</i> Impairs Glucose Metabolism and Estrous Cycling in Female Mice. | Fernandez MO et al. | — | 2017 | → |
| Changes in PPARδ expression in a rat model of stress-induced depression. | Liu KF et al. | — | 2017 | → |
| Glucocorticoid-Induced Leucine Zipper in Central Nervous System Health and Disease. | Srinivasan M et al. | — | 2017 | → |
| Macrophage Transcriptional Profile Identifies Lipid Catabolic Pathways That Can Be Therapeutically Targeted after Spinal Cord Injury. | Zhu Y et al. | — | 2017 | → |
| Pathophysiology Associated with Traumatic Brain Injury: Current Treatments and Potential Novel Therapeutics. | Pearn ML et al. | — | 2017 | → |
| PPARβ/δ activation protects against corticosterone-induced ER stress in astrocytes by inhibiting the CpG hypermethylation of microRNA-181a. | Ji J et al. | — | 2017 | → |
| Regulation of brain PPARgamma2 contributes to ketogenic diet anti-seizure efficacy. | Simeone TA et al. | — | 2017 | → |
| The toll-like receptor 2 agonist Pam3CSK4 is neuroprotective after spinal cord injury. | Stivers NS et al. | — | 2017 | → |
| Treatment with albumin-hydroxyoleic acid complex restores sensorimotor function in rats with spinal cord injury: Efficacy and gene expression regulation. | Avila-Martin G et al. | — | 2017 | → |
| Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish. | Ashikawa Y et al. | — | 2016 | → |
| Evidence that activation of nuclear peroxisome proliferator-activated receptor alpha (PPARα) modulates sleep homeostasis in rats. | Murillo-Rodríguez E et al. | — | 2016 | → |
| Protective features of peripheral monocytes/macrophages in stroke. | Gliem M et al. | — | 2016 | → |
| Rosiglitazone attenuates inflammation and CA3 neuronal loss following traumatic brain injury in rats. | Liu H et al. | — | 2016 | → |
| Activation of central PPAR-γ attenuates angiotensin II-induced hypertension. | Yu Y et al. | — | 2015 | → |
| Clinical implications of leukocyte infiltration at the choroid plexus in (neuro)inflammatory disorders. | Demeestere D et al. | — | 2015 | → |
| Complex role of peroxisome proliferator activator receptors (PPARs) in nociception. | Giniatullin R et al. | — | 2015 | → |
| Macrophage activation and its role in repair and pathology after spinal cord injury. | Gensel JC et al. | — | 2015 | → |
| Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | Blednov YA et al. | — | 2015 | → |
| Fetal alcohol spectrum disorders and neuroimmune changes. | Drew PD et al. | — | 2014 | → |
| Role of PPAR γ in the Differentiation and Function of Neurons. | Quintanilla RA et al. | — | 2014 | → |